Pre-mRNA splicing is catalyzed by the spliceosome, a dynamic molecular machine formed by the ordered interaction of the U1, U2, U4/U6 and U5 snRNPs, plus many non-snRNP proteins (reviewed in ref. 1). U1 and U2 interact first with the pre-mRNA to generate the spliceosomal A complex, which is then converted to the pre-catalytic B complex by the stable association of the preformed U4/U6−U5 tri-snRNP. After dramatic rearrangements, including destabilization of U1 and U4, the B complex is activated. The first catalytic step of splicing, which involves cleavage at the pre-mRNA's 5′ splice site and ligation of the intron's 5′ end to the branch site, subsequently ensues, generating the C complex. The C complex then catalyzes the second step of splicing, during which the 3′ splice site is cleaved and the 5′ and 3′ exon are ligated to form mRNA.
a r t i c l e s
Pre-mRNA splicing is catalyzed by the spliceosome, a dynamic molecular machine formed by the ordered interaction of the U1, U2, U4/U6 and U5 snRNPs, plus many non-snRNP proteins (reviewed in ref. 1) . U1 and U2 interact first with the pre-mRNA to generate the spliceosomal A complex, which is then converted to the pre-catalytic B complex by the stable association of the preformed U4/U6−U5 tri-snRNP. After dramatic rearrangements, including destabilization of U1 and U4, the B complex is activated. The first catalytic step of splicing, which involves cleavage at the pre-mRNA's 5′ splice site and ligation of the intron's 5′ end to the branch site, subsequently ensues, generating the C complex. The C complex then catalyzes the second step of splicing, during which the 3′ splice site is cleaved and the 5′ and 3′ exon are ligated to form mRNA.
Protein-protein interactions have a key role in tri-snRNP formation and tri-snRNP integration into the spliceosome. In humans, at least two proteins mediate tri-snRNP formation, namely the U4/U6-associated PRP31 protein (also known as PRPF31) and the U5-associated PRP6 protein (also known as PRPF6) 2, 3 . Human PRP31 is an essential splicing factor 2 , and specific mutations in PRP31 are associated with autosomal dominant retinitis pigmentosa 4 . Stable integration of the human tri-snRNP into the spliceosome requires several proteins, including PRP28 (also known as DDX23) 5 , the tri-snRNP proteins SAD1 (also known as USP39) and SNU66 (also known as SART1) 6 , the U2-associated SPF30 (also known as SMNDC1) protein 7, 8 and SR (serine-arginine−rich) proteins 9 .
Reversible protein phosphorylation affects most cellular activities in eukaryotes, including pre-mRNA splicing. Both the phosphorylation and dephosphorylation of spliceosomal proteins are important during the splicing process 5, [10] [11] [12] [13] [14] [15] . Known human spliceosomal and snRNP phosphoproteins include members of the SR protein family 16, 17 , U1-70K (also known as SNRNP70) 18 , SF3B155 (also known as SF3B1) 19 , PRP28 (ref. 5 ) and several U4/U6−U5 tri-snRNP proteins 20 . SR proteins facilitate the association of snRNPs with the pre-mRNA during spliceosome assembly, and phosphorylation is essential for SR protein activity 16, 21 and enhances their interactions with other spliceosomal proteins 13 . Human PRP28, a U5 snRNP protein, is phosphorylated by the protein kinase SRPK2, and this event is a prerequisite for tri-snRNP addition during B complex formation 5 . The U2-associated SF3B155 protein is specifically hyperphosphorylated just before step I of splicing 19 and is dephosphorylated by the PP1 or PP2A phosphatases during step II of splicing 15 .
Several protein kinases are involved in splicing, although in many cases, their specific targets are not well understood. Kinases known to phosphorylate the RS-rich regions of SR proteins and other spliceosomal proteins include members of the Clk/Sty family 22 , DNA topoisomerase 1 (ref. 23 ) and members of the SRPK family [24] [25] [26] . Prp4 kinase (Prp4K) is essential for pre-mRNA splicing in Schizosaccharomyces pombe 27 , but the molecular mechanism of Prp4K action and the stage of splicing at which it acts are unknown. Prp4K belongs to the Clk/Sty family 28 and is a Ser/Thr kinase. In higher eukaryotes, Prp4K contains, in addition to its highly conserved kinase domain, a neighboring RS domain and an N-terminal lysine-rich domain, both of which are lacking in S. pombe 29 . Prp4K can phosphorylate itself 29 , the SR protein ASF (also known as SF2) 30, 31 and Prp6 (refs. 29, 32) . Mammalian and S. pombe Prp4K interact physically with Prp6 (refs. 29, 32) . Furthermore, S. pombe Prp4K interacts genetically with the proteins Prp8 and Brr2, which facilitate spliceosome activation 33 . Thus, Prp4K was proposed to have a role in the formation of catalytically active spliceosomes 33 , although formal proof for this is currently lacking. Prp4K is also involved in mitosis 34 and was implicated in coupling pre-mRNA splicing with chromatin-remodeling events that regulate transcription 29 .
Here we demonstrate that the human tri-snRNP−associated proteins PRP6 and PRP31 are phosphorylated during spliceosomal B complex formation and, further, that their phosphorylation, as well as pre-mRNA splicing, is dependent on human PRP4K (also known as PRPF4B). We also demonstrate that stable association of the tri-snRNP during B complex formation is dependent on PRP4K, suggesting that PRP6 and PRP31 phosphorylation by this kinase has a key role in promoting tri-snRNP integration during spliceosome assembly.
RESULTS

PRP6 and PRP31 are modified during spliceosome assembly
To screen for proteins potentially modified during splicing, we initially performed immunoblotting with proteins isolated from human snRNPs or from purified spliceosomal B complexes. We detected a single band in purified tri-snRNPs by antibodies specific for human SNU66, PRP6 and PRP31 (Fig. 1a) , but we observed multiple, slower-migrating bands with antibodies against PRP6 and PRP31 when proteins from purified B complexes were analyzed. This indicates that human PRP6 and PRP31 are modified during spliceosome assembly and that B complexes predominantly contain modified forms of these proteins.
Identification of phosphorylated PRP6 and PRP31 residues MS analyses revealed that, in purified B complexes, human PRP6 and PRP31 are phosphorylated at multiple sites. In PRP6, we detected phosphoserines at positions 263 and 279, and phosphothreonines at positions 205, 266 and 275 ( Fig. 1b and Supplementary Fig. 1 ). Most of these sites are clustered just upstream of the TPR repeat region of PRP6. An alignment of the phosphorylated region of human PRP6 with homologs from Mus musculus, Drosophila melanogaster, Caenhorhabditis elegans, S. pombe and Saccharomyces cerevisiae revealed that, with the exception of Prp6 in S. cerevisiae, Thr275 and Ser279 (amino acid positions according to human PRP6) are 100% conserved (Supplementary Fig. 2 ). Ser263 and Thr266 are also conserved, although in some organisms serine is replaced by threonine and vice versa. In human PRP31, we detected phosphoserines at positions 439, 498 and either 445 or 446 (MS could not distinguish between these two sites) and potentially at serines 450 or 451 (a conclusive assignment at either of these sites could not be made), and we found phosphothreonines at positions 440 and 455 ( Fig. 1b and Supplementary Fig. 1 ). Similar to PRP6, most of these residues (except Ser445, Ser446 and Ser498) are highly conserved across evolution, with the notable exception of S. cerevisiae (Supplementary Fig. 2 ). This suggests that these amino acids have an important function and that they are phosphorylated not only in humans but also in a wide variety of organisms.
To analyze human PRP6 and PRP31 phosphorylation in more detail, we raised antibodies against phosphorylated peptides comprising amino acids 271−279 of PRP6 or 434−453 of PRP31, containing the above phosphorylation sites. Each of these antibodies recognized a band that migrated slower than the one detected in purified tri-snRNPs by antibodies directed against a nonphosphorylated region of PRP6 or PRP31 (Fig. 1c) . Thus, at least one of the slower-migrating PRP6 and PRP31 species observed in purified B complexes is phosphorylated.
PRP31 phosphorylation requires spliceosome formation
We next performed splicing in vitro with HeLa nuclear extract and followed the kinetics of PRP31 phosphorylation via western blotting. Owing to the lower activity of the anti−phospho-PRP6 antibodies, it was not possible to unequivocally detect phosphorylated PRP6 in nuclear extract. In the presence of adenovirus-derived MINX premRNA, PRP31 was first phosphorylated after 2 min (Fig. 2a, lane 3) , which correlates with the appearance of the B complex (Fig. 2b, lane 3) . The amount of phosphorylated PRP31 increased before reaching a plateau after 4 min. When no pre-mRNA substrate was added, we observed only a low level of phospho-PRP31 (Fig. 2a, lanes 9−16) . We first detected phosphorylation of SF3B155, which occurs after B complex formation 19 , after 10 min of splicing, coinciding with the appearance of the C complex (Fig. 2a,b, lane 7) . Thus, phosphorylation 
of PRP31 in HeLa nuclear extract is dependent on spliceosome assembly and temporally precedes SF3B155 phosphorylation.
Phosphorylation of PRP6 and PRP31 is dependent on PRP4K
Our data suggest that tri-snRNP integration into the spliceosome is accompanied by phosphorylation of human PRP6 and PRP31. To dissect the role of PRP4K in PRP6 and PRP31 phosphorylation, and also in splicing, we first immunodepleted it from HeLa nuclear extract under high-salt conditions. Western blot analysis of mock-depleted versus PRP4K-depleted (∆PRP4K) extract revealed quantitative depletion of PRP4K (Fig. 3a) .
Owing to residual antibody in the ∆PRP4K extract, it was not possible via western analysis to directly assay the phosphorylation status of PRP31, as it co-migrates with the immunoglobulin G (IgG) heavy chain. Thus, to determine whether phosphorylation of PRP6 and/or PRP31 was affected, we first performed splicing in mock-depleted or ∆PRP4K extract with MINX pre-mRNA containing aptamers of the MS2 phage coat protein (pre-bound with MS2-maltose-binding protein (MBP)). We then affinity selected spliceosomal complexes and analyzed them by western blotting. Whereas phosphorylated PRP6 and PRP31 were present in complexes formed in the mockdepleted extract, we no longer observed them in ∆PRP4K extract (Fig. 3b, lanes 1 and 2) . However, we detected nonphosphorylated PRP6 and PRP31 in both cases (Fig. 3b, lanes 1 and 2) , suggesting that these proteins (presumably in the form of the tri-snRNP) are still recruited to spliceosomes. To confirm that PRP4K is responsible for the altered phosphorylation status of human PRP6 and PRP31, we overexpressed His-tagged wild-type PRP4K, as well as two mutated forms with single-residue changes in the ATP-binding site (M1 with a K717I mutation) or predicted active site (M2 with a D815A mutation) (Supplementary Fig. 3 ). Upon complementation of the ∆PRP4K extract with purified wild-type PRP4K, but not an inactive form of PRP4K, we detected phosphorylated PRP6 and PRP31 in the affinityselected complexes (Fig. 3b , lane 3, and Supplementary Fig. 4) . Thus, the phosphorylation of both proteins in splicing extract is dependent on PRP4K activity.
Purified human PRP4K phosphorylates PRP31 in vitro
Human PRP4K was previously shown to directly phosphorylate PRP6 in vitro and also to phosphorylate itself 29, 32 . To test whether PRP31 is also a direct target of this kinase, we performed in vitro phosphorylation studies with purified PRP4K and recombinant PRP31 fused to MBP. Consistent with previous reports, incubation of purified PRP4K with (γ-32 P)ATP led to the phosphorylation of an ~150-kDa protein, which probably corresponds to autophosphorylated PRP4K (Fig. 3c, lane 5) . In contrast, we did not observe additional 32 P-labeled bands when we incubated purified PRP4K with MS2-MBP, demonstrating that MBP is not phosphorylated by this kinase (Fig. 3c, lane 6 ). Upon addition of purified PRP4K to MBP-PRP31, we observed radiolabeled bands migrating at the position of MPB-PRP31 (~100 kDa) and at the position of autophosphorylated PRP4K (Fig. 3c, lane 8) . The radiolabeled 100-kDa protein was precipitated by both anti-PRP31 and anti−phospho-PRP31 antibodies, but was not precipitated in the absence of antibody (Fig. 3c, lanes  9−11) , confirming that PRP31 was phosphorylated. Phosphorylated PRP4K was also precipitated by the anti−phospho-PRP31 antibodies, suggesting that they cross-react with PRP4K or, alternatively, that phosphorylated PRP4K associates with phosphorylated PRP31 and is thereby co-precipitated.
In vitro phosphorylation with a nonphosphorylated or phosphorylated PRP31 peptide encompassing amino acids 434−453 (VYGGKS P T P IRDRSSGT P ASSVA, where P indicates phosphorylation), confirmed that wild-type PRP4K, but neither of the PRP4K mutants, specifically phosphorylates in vitro one or more of the phosphoserines and phosphothreonines detected by MS (Fig. 3d) . Taken together, these studies demonstrate that PRP31 is a substrate of human PRP4K in vitro and, together with PRP6, is therefore probably directly phosphorylated by this kinase in HeLa nuclear extract under splicing conditions.
B complex formation is reduced in PRP4K extract
To determine the role of human PRP4K in splicing, we performed an in vitro splicing assay with MINX pre-mRNA and either mock-depleted or ∆PRP4K nuclear extract. Both steps of splicing were clearly reduced in ∆PRP4K extract as compared to the mock-depleted extract (Fig. 4a,  lanes 2 and 3) . Notably, splicing could be restored by addition of purified wild-type PRP4K but not by inactivated PRP4K (that is, M1 or M2) (Fig. 4a , lanes 4−6), consistent with previous studies in S. pombe indicating a requirement for active Prp4K in splicing 32, 33 . We obtained similar results with a β-globin pre-mRNA substrate ( Supplementary  Fig. 5 ), demonstrating that the inhibitory effect of PRP4K depletion is not specific for the MINX pre-mRNA. Thus, similar to its S. pombe counterpart, human PRP4K is required for splicing in vitro.
To determine at what step of splicing human PRP4K acts, we analyzed splicing complex formation. Relative to mock-depleted extract, we observed a clear decrease in B complex formation, with a corresponding increase in A complex, when splicing was performed with the ∆PRP4K extract (Fig. 4b, lanes 2 and 3) . Furthermore, we could restore B complex formation by adding wild-type, but not mutant, PRP4K (Fig. 4b, lanes  4−6) . These data clearly demonstrate a role for human PRP4K in spliceosome assembly at the stage of tri-snRNP addition.
Tri-snRNP levels are not affected by PRP4K depletion
Both human PRP6 and PRP31 have essential roles in the stability of the tri-snRNP in vivo 3 and in vitro 2 . As these proteins are no longer phosphorylated in ∆PRP4K extract, tri-snRNP stability might also be affected, leading to a reduction in B complex formation. To assay for changes in tri-snRNP stability, we subjected mock-depleted and ∆PRP4K extract to glycerol gradient centrifugation and monitored the distribution of U4/U6−U5 tri-snRNPs by northern blotting. We did not detect a change in the distribution of the U4, U5 or U6 small nuclear RNAs (snRNAs) upon PRP4K depletion (Fig. 5a,b, above) . Similarily, the distribution of PRP31 was also not affected (Fig. 5a,b,  below) . Thus, the block in B complex formation is not a consequence of reduced amounts of tri-snRNP in ∆PRP4K extract.
In Figure 4 , we analyzed B complex formation on native gels in the presence of heparin, which can 'strip' less stably associated components from the pre-mRNA. Indeed, affinity selection of spliceosomal complexes in the absence of heparin (Fig. 5b) revealed that PRP6 and PRP31-and thus presumably tri-snRNPscan still associate with the pre-mRNA in ∆PRP4K extract. To test whether tri-snRNPs still dock with A complexes after PRP4K depletion, we performed pull-down experiments with amylose beads after incubating MS2-MBP-bound MINX pre-mRNA under splicing conditions in mock or ∆PRP4K extract for 10 min to allow B complex formation. We observed nearly identical amounts of co-purified U4, U5 and U6 snRNA in mock-depleted versus ∆PRP4K extract (Fig. 5c, lanes 3 and 4) . This indicates that PRP4K is not required for initial tri-snRNP docking but, rather, for the stable (that is, heparin-resistant) integration of the tri-snRNP during a r t i c l e s B complex formation. As splicing was inhibited by PRP4K depletion, our results further indicate that although tri-snRNPs can bind to pre-spliceosomes in the absence of PRP4K, the resultant spliceosomal complexes are functionally compromised.
DISCUSSION
Here we show that the human tri-snRNP proteins PRP6 and PRP31 are phosphorylated after tri-snRNP incorporation into the spliceosomal B complex, and we provide evidence that both proteins are directly phosphorylated by PRP4 kinase in this complex. Human PRP4K activity is required not only for the phosphorylation of PRP6 and PRP31, but also for the assembly of stable, functional B complexes. This suggests in turn that phosphorylation of these proteins helps to stabilize the interaction of the tri-snRNP with pre-spliceosomes. Taken together, our data provide new insights into the molecular mechanism of action of PRP4K during splicing.
Phosphorylation of PRP6 and PRP31 is dependent on PRP4K
Our data strongly suggest that human PRP6 and PRP31 are directly phosphorylated by PRP4K during splicing. PRP6 and PRP31 are first phosphorylated after their incorporation into the spliceosomal B complex, suggesting that their phosphorylation is tightly regulated and probably mediated and/or triggered by a B complex component. Notably, PRP4K is the only kinase that is consistently detected by MS in purified human B complexes. Furthermore, PRP4K phosphorylates human PRP6 (refs. 29,32) and PRP31 (Fig. 3) in vitro, and the phosphorylation of both proteins is greatly reduced in ∆PRP4K extract (Fig. 3) . Thus, it is highly likely that both proteins are directly phosphorylated by human PRP4K both in vitro and in vivo. Consistent with the idea that PRP6 and PRP31 are substrates for PRP4K in vivo, the amino acids of human PRP6 and PRP31 that are phosphorylated in extract under splicing conditions (Supplementary Fig. 2 ) are evolutionarily conserved, except in S. cerevisiae, in which Prp4K is absent.
The role of PRP6 and PRP31 phosphorylation in splicing
The U5-associated Prp6 protein has a bridging role in both human and yeast U4/U6−U5 tri-snRNPs 35, 36 , through its interaction with the U4/U6-associated Prp31 protein 36 . In humans, PRP31 is also required for the formation of tri-snRNPs both in vitro 2 and in vivo 3 . The identification of an early role for these proteins in higher eukaryotes does not exclude the possibility that they also act at subsequent steps. Indeed, although not required for yeast tri-snRNP formation, S. cerevisiae Prp31 promotes stable association of the tri-snRNP with the pre-mRNA during B complex formation 37 . This is consistent with the idea that human PRP31 also contributes to the stable integration of tri-snRNPs into human B complexes, and our data further suggest that phosphorylation of PRP31 would be required for its putative stabilizing effect. Phosphorylation of PRP31 could stabilize tri-snRNP association with the A complex by enhancing or promoting protein-protein interactions involving this protein. Human PRP31 interacts with the TPR repeat region of PRP6 (ref. 38) , and its NOP domain also binds a composite RNP site within the U4/U6 snRNP that consists of the U4-15.5K (also known as NHP2L1) protein and the U4 snRNA 39 . Human PRP31 has not been reported to interact with other spliceosomal proteins. However, it is conceivable that the PRP31-PRP6 interaction, which is crucial for stable tri-snRNP formation, must be enhanced or in some way altered via phosphorylation to ensure tri-snRNP stability within the B complex or to enhance tri-snRNP interactions with A complex components. Indeed, both of these proteins seem to be phosphorylated concomitantly, supporting the idea that a shared function of these proteins is targeted by phosphorylation. Notably, human PRP6 interacts with a number of other spliceosomal proteins, including SNU66 (ref. 38) . In budding yeast, Snu66 is required for splicing and seems to interact with one or more components of the U2 snRNP 40 , which is a major subunit of the spliceosomal A complex. Human SNU66 was shown to be essential for B complex formation in vitro 6 , and it is conceivable that its function is modulated by phosphorylation of its interaction partner, PRP6. Additionally or alternatively, the phosphorylation of these proteins may be important for more downstream events. For example, phosphorylation of human PRP6 and PRP31 might contribute to the remodeling of tri-snRNP components during spliceosome activation, when the U4/U6 snRNA base pairing interactions are disrupted and U4 snRNA, together with PRP31 and other U4-associated proteins, is destabilized or released from the spliceosome. As decribed above, PRP31 interacts directly with components of the U4/U6 snRNP and also PRP6. PRP6, in turn, contacts several proteins that have key roles during the catalytic activation of the spliceosome, including PRP8 (also known as PRPF8), BRR2 (also known as SNRNP200) and SNU114 (also known as EFTUD2) 38 . Thus, PRP6 and/or PRP31 phosphorylation could potentially modulate the activity of these proteins. Consistent with this idea, S. pombe Prp6 (denoted Prp1) interacts genetically with both Brr2 and Prp8, suggesting a functional relationship between Prp6 and these proteins 33 . PRP31 and PRP6 are destabilized and/or lost from human spliceosomes during catalytic activation, together with other U4/U6 and tri-snRNP proteins 41 , and phosphorylation (or even subsequent dephosphorylation) could potentially be a prerequisite for their release from the spliceosome.
The molecular mechanism of PRP4K action
Our data reveal that human PRP4K is not required for tri-snRNP stability, nor for its initial docking to the pre-spliceosome (Fig. 5) , but instead for stable tri-snRNP integration (Fig. 4) . Probable targets of PRP4K that mediate stable tri-snRNP integration are PRP6 and PRP31. However, we cannot exclude the possibility that other targets of this kinase additionally or alternatively have key roles in this process. For example, at least one SR protein (ASF) is phosphorylated in vitro by PRP4K 30, 31 , and loss of SR protein phosphorylation upon PRP4K depletion could theoretically contribute to reduced B complex stability. However, other kinases that phosphorylate SR proteins should still be active in ∆PRP4K extract, and individual SR proteins can functionally substitute for each other at this stage 9 . Other proteins involved in tri-snRNP integration during spliceosome assembly-for example, PRP28, SNU66 or SAD1 (refs. 5,6)-could also potentially be substrates of PRP4K. However, at present, the modification status of SNU66 and SAD1 is unclear. Phosphorylation of human PRP28 is required for B complex formation but is mediated by the kinase SRPK2 (ref. 5).
Multiple phosphorylation events during B complex assembly
In higher eukaryotes, post-translational modifications act as molecular switches during spliceosome assembly and catalytic activation, and thus have important regulatory roles in the progression of splicing. Our data, together with that from previous studies on PRP28, suggest that tri-snRNP addition during human B complex formation is dependent on multiple phosphorylation events, including phosphorylation of PRP28 (ref. 5 ) and probably also of PRP6 and PRP31. Thus, this stage of splicing is potentially a 'hot spot' for regulation.
S. cerevisiae lacks Prp4K, and the serine and threonine residues of PRP6 and PRP31 that are phosphorylated in humans are not conserved in S. cerevisiae, suggesting differential requirements for stable tri-snRNP association. In S. cerevisiae, Prp28 is required for stable tri-snRNP a r t i c l e s addition to the A complex 42 . Phosphorylated PRP28 is required for B complex formation in humans, but whether it stabilizes tri-snRNP association during this stage is not known 5 . Furthermore, the kinase SRPK2, which is also essential for human B complex formation, is absent in S. cerevisiae. This kinase phosphorylates RS-rich domains that, in higher eukayotes, are typically found in SR proteins and other spliceosomal proteins (including PRP28) but are nearly absent in S. cerevisiae. Indeed, there seems to be generally fewer phosphorylation events during splicing in S. cervisiae, and thus fewer regulatory targets or switches. This is consistent with the lack of alternative splicing events in yeast, and also with the more flexible nature of interactions among spliceosomal components in higher eukaryotes, which may therefore be more susceptible to fine-tuning by post-translational modifications.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
ONLINE METHODS
Immunizations and western blot analyses. To generate phosphospecific human PRP6 or PRP31 antibodies, we immunized rabbits with the following phosphopeptides (phosphorylated ( P ) threonines and serines are indicated): KGYLT P DLNS P (PRP6 residues 271−279) or VYGGKS P T P IRDRSSGT P ASSVA (PRP31 residues 434−453). To obtain phosphospecific SF3B155 antibodies, we immunized rabbits with the phosphopeptide HGSGWAET P RRTDRGG (SF3B155 residues 306−320). Before use, we passed the phosphospecific antisera over a column containing nonphosphorylated cognate peptide, to remove nonphosphospecific antibodies. For western blotting, we separated proteins on a 10% SDSpolyacrylamide gel, transferred them to nitrocellulose and analyzed them using an enhanced chemoluminescence (ECL) detection kit (Pierce) with the following antibodies: Prp4K 34 In vitro splicing. We prepared HeLa nuclear extract as described 43 . Splicing reactions contained 2−10 nM 32 P-labeled MINX pre-mRNA 44 or β-globin premRNA, 65 mM KCl, 3 mM MgCl 2 , 2 mM ATP, 20 mM creatine phosphate and 40% (v/v) HeLa nuclear extract. We incubated the reactions at 30 °C for the indicated time periods. We analyzed the pre-mRNA and splicing intermediates and products by denaturing PAGE and the spliceosomal complexes by native PAGE, as described 2 .
Purification of tri-snRNPs and spliceosomal B complexes. We obtained human U4/U6−U5 tri-snRNPs by anti-m 3 G immunoaffinity chromatography and subsequent glycerol gradient centrifugation 45 . We purified the human spliceosomal B complexes from in vitro splicing reactions by the MS2 affinity-selection method 46 . Briefly, we incubated the MINX pre-mRNA substrate (containing MS2 aptamers bound by MBP-MS2 protein) for 5−10 min under splicing conditions to allow B complex formation. We isolated the B complexes using glycerol gradient centrifugation followed by amylose affinity selection of gradient fractions containing the B complex. In some cases (as indicated), spliceosomal complexes were affinity selected directly from the splicing reaction.
Immunodepletion of PRP4 kinase. To immunodeplete human PRP4K, we first adjusted the NaCl concentration of HeLa nuclear extract to 1M. We then added the extract to Protein A−Sepharose beads bound by anti-PRP4K antibodies 34 and incubated the mixture with end-over-end rotation for 1h at 4 °C. We then repeated the procedure with a second aliquot of antibody-bound protein A− Sepharose beads. We recovered the nuclear extract and dialyzed it twice for 1.5 h at 4 °C against Roeder D buffer (20 mM HEPES-KOH (pH 7.9), 100 mM KCl, 1.5. mM MgCl 2 , 0.2 mM EDTA (pH 8.0), 1 mM dithioerythritol, 0.5 mM PMSF, 20% (v/v) glycerol). Mock-depleted extract was prepared in an identical manner except that the antibody was omitted. For splicing-complementation studies, we added 450 ng of recombinant wild-type or mutant human PRP4K to splicing reactions containing ∆PRP4K nuclear extract. To analyze the integrity of U4/U6−U5 tri-snRNPs after PRP4K immunodepletion, mock-depleted or ∆PRP4K extract was fractionated on a 10-30% (v/v) glycerol gradient by centrifugation for 2 h at 488,576g (r max ). We determined the distribution of U4, U5 and U6 snRNAs across the gradient by northern analysis, and that of tri-snRNP−associated proteins by western analysis.
Expression of recombinant PRP4 kinase. His-tagged, human PRP4K was expressed in the baculovirus system. We obtained the human PRP4 kinase cDNA sequence from Invitrogen (CloneID: IOH45196) in a Gateway entry vector and transformed it into the pDEST 10 vector with an N-terminal His-tag, according to the manufacturer's protocol. We produced the PRP4K mutants M1 (K717I) and M2 (D815A) by site-directed mutagenesis of the latter vector and verified them via sequencing. Recombination was performed in Escherichia coli strain DH10Ba, and the resulting PRP4K-containing bacmid was purified according to the manufacturer's protocol. We produced viral stocks in SF9 insect cells. For purification of recombinant PRP4K, we harvested High Five insect cells 48 h after transfection with baculovirus. We lysed the cells in suspension buffer (50 mM Tris-HCl (pH 8.0), 1 M NaCl, 10 mM imidazole) by repeated freezing and thawing. The cleared lysate was applied to a Ni-agarose column, washed with buffer W (50 mM Tris-HCl (pH 8.0), 1 M NaCl, 20 mM imidazole), and purified PRP4K was eluted with elution buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 400 mM imidazole). Purified PRP4K was dialyzed against Roeder D buffer.
In vitro kinase assays. We assessed the activity of recombinant wild-type or mutant human PRP4K (as indicated) by incubating 450 ng of purified kinase with either 100 µg of phosphorylated or nonphosphorylated PRP31 peptide (residues 434−453; see above) or 7 µg of recombinant MBP-PRP31 (ref. 47) or MS2-MBP in the presence of (γ-32 P)ATP for 10 min at 30 °C. We analyzed the peptides by thin-layer chromatography and the proteins by 10% SDS-PAGE, followed by autoradiography. We performed immunoprecipitation of phosphorylated proteins essentially as described 5 .
Identification of phosphorylated amino acids by mass spectrometry. Proteins recovered from purified B complexes were separated by SDS-PAGE and stained with Coomassie Brilliant Blue. We cut entire lanes of the gel into multiple slices, and the proteins were digested in-gel with trypsin, extracted as described 48 and dried under vacuum. Phosphopeptides were enriched by titanium dioxide (TiO 2 ; GL Sciences) as described 49 . For ESI MS/MS analysis, we first loaded the enriched peptides onto an in-house−packed C18 trap column (15 × 0.15 mm, Nucleosil 100-5 C18; Macherey-Nagel). The retained peptides were eluted and separated on an analytical C18 capillary column (300 × 0.075 mm, Nucleosil 100-5 C18) at a flow rate of 300 nl min −1 , with a gradient from 7.5% to 37.5% (v/v) acetonitrile in 0.1% (v/v) formic acid for 60 min, 120 min or 240 min, using an Agilent Technologies 1100 nano-flow LC system coupled to a Q-TOF mass spectrometer (Waters Q-Tof Ultim). We recorded MS and MS/MS spectra under standard conditions and searched used MASCOT v2.2 against the NCBI nr database limited to human taxonomy with the following criteria: peptide mass tolerance, 50 ppm; MS/MS ion mass tolerance, 0.25 Da; allow up to two missed cleavages; variable modifications were phosphorylation of serine, threonine and tyrosine, methionine oxidation and cysteine carboxyamidomethylation. All fragment spectra of phosphorylated peptides were inspected manually for the presence of 69-Da dihydroalanine (phosphorylated serine after loss of H 3 PO 4 ) and 83-Da dihydroaminobutyric acid (phosphorylated threonine after loss of H 3 PO 4 ).
